Heart Failure With Preserved Ejection Fraction In Perspective

Marc A. Pfeffer, Amil M. Shah, Barry A Borlaug

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Approximately half of the patients with signs and symptoms of heart failure have a left ventricular ejection fraction that is not markedly abnormal. Despite the historically initial surprise, heightened risks for heart failure specific major adverse events occur across the broad range of ejection fraction, including normal. The recognition of the magnitude of the problem of heart failure with preserved ejection fraction in the past 20 years has spurred an explosion of clinical investigation and growing intensity of informative outcome trials. This article addresses the historic development of this component of the heart failure syndrome, including the epidemiology, pathophysiology, and existing and planned therapeutic studies. Looking forward, more specific phenotyping and even genotyping of subpopulations should lead to improvements in outcomes from future trials.

Original languageEnglish (US)
Pages (from-to)1598-1617
Number of pages20
JournalCirculation research
Volume124
Issue number11
DOIs
StatePublished - May 24 2019
Externally publishedYes

Fingerprint

Heart Failure
Explosions
Stroke Volume
Signs and Symptoms
Epidemiology
Therapeutics

Keywords

  • clinical trials, phase III
  • epidemiology
  • heart failure
  • heart failure, diastolic

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Heart Failure With Preserved Ejection Fraction In Perspective. / Pfeffer, Marc A.; Shah, Amil M.; Borlaug, Barry A.

In: Circulation research, Vol. 124, No. 11, 24.05.2019, p. 1598-1617.

Research output: Contribution to journalArticle

Pfeffer, Marc A. ; Shah, Amil M. ; Borlaug, Barry A. / Heart Failure With Preserved Ejection Fraction In Perspective. In: Circulation research. 2019 ; Vol. 124, No. 11. pp. 1598-1617.
@article{0ba0ccd426844a3196b647afe12d33ef,
title = "Heart Failure With Preserved Ejection Fraction In Perspective",
abstract = "Approximately half of the patients with signs and symptoms of heart failure have a left ventricular ejection fraction that is not markedly abnormal. Despite the historically initial surprise, heightened risks for heart failure specific major adverse events occur across the broad range of ejection fraction, including normal. The recognition of the magnitude of the problem of heart failure with preserved ejection fraction in the past 20 years has spurred an explosion of clinical investigation and growing intensity of informative outcome trials. This article addresses the historic development of this component of the heart failure syndrome, including the epidemiology, pathophysiology, and existing and planned therapeutic studies. Looking forward, more specific phenotyping and even genotyping of subpopulations should lead to improvements in outcomes from future trials.",
keywords = "clinical trials, phase III, epidemiology, heart failure, heart failure, diastolic",
author = "Pfeffer, {Marc A.} and Shah, {Amil M.} and Borlaug, {Barry A}",
year = "2019",
month = "5",
day = "24",
doi = "10.1161/CIRCRESAHA.119.313572",
language = "English (US)",
volume = "124",
pages = "1598--1617",
journal = "Circulation Research",
issn = "0009-7330",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Heart Failure With Preserved Ejection Fraction In Perspective

AU - Pfeffer, Marc A.

AU - Shah, Amil M.

AU - Borlaug, Barry A

PY - 2019/5/24

Y1 - 2019/5/24

N2 - Approximately half of the patients with signs and symptoms of heart failure have a left ventricular ejection fraction that is not markedly abnormal. Despite the historically initial surprise, heightened risks for heart failure specific major adverse events occur across the broad range of ejection fraction, including normal. The recognition of the magnitude of the problem of heart failure with preserved ejection fraction in the past 20 years has spurred an explosion of clinical investigation and growing intensity of informative outcome trials. This article addresses the historic development of this component of the heart failure syndrome, including the epidemiology, pathophysiology, and existing and planned therapeutic studies. Looking forward, more specific phenotyping and even genotyping of subpopulations should lead to improvements in outcomes from future trials.

AB - Approximately half of the patients with signs and symptoms of heart failure have a left ventricular ejection fraction that is not markedly abnormal. Despite the historically initial surprise, heightened risks for heart failure specific major adverse events occur across the broad range of ejection fraction, including normal. The recognition of the magnitude of the problem of heart failure with preserved ejection fraction in the past 20 years has spurred an explosion of clinical investigation and growing intensity of informative outcome trials. This article addresses the historic development of this component of the heart failure syndrome, including the epidemiology, pathophysiology, and existing and planned therapeutic studies. Looking forward, more specific phenotyping and even genotyping of subpopulations should lead to improvements in outcomes from future trials.

KW - clinical trials, phase III

KW - epidemiology

KW - heart failure

KW - heart failure, diastolic

UR - http://www.scopus.com/inward/record.url?scp=85066866746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066866746&partnerID=8YFLogxK

U2 - 10.1161/CIRCRESAHA.119.313572

DO - 10.1161/CIRCRESAHA.119.313572

M3 - Article

VL - 124

SP - 1598

EP - 1617

JO - Circulation Research

JF - Circulation Research

SN - 0009-7330

IS - 11

ER -